Researchers at the University of Minnesota have achieved a breakthrough in treating advanced gastrointestinal (GI) cancers using CRISPR/Cas9 gene-editing technology. Published in Lancet Oncology, their first-in-human clinical trial demonstrated the therapy’s safety and potential effectiveness, with one patient experiencing complete remission.
The study focused on modifying tumor-infiltrating lymphocytes (TILs), a type of immune cell, by deactivating the CISH gene using CRISPR/Cas9. This genetic alteration enhanced the TILs’ ability to target and destroy cancer cells. The trial involved 12 patients with highly metastatic, end-stage GI cancers. Notably, the treatment caused no serious side effects, and several patients saw their cancer growth halt, with one achieving complete tumor disappearance for over two years.
Dr. Branden Moriarity, a lead researcher, explained that CISH typically hinders T cells from recognizing tumors, making it an ideal target for gene editing. Unlike conventional therapies requiring repeated doses, this approach provides a permanent solution by embedding the modification directly into the T cells.
The team successfully produced over 10 billion engineered TILs, marking a milestone in scalable, clinically viable gene-edited therapies. However, the process remains expensive and complex, prompting ongoing efforts to refine production and replicate the exceptional response seen in the trial. This pioneering study offers hope for patients with advanced GI cancers, showcasing CRISPR’s potential to revolutionize cancer treatment. Future research will focus on optimizing the therapy’s efficacy and accessibility, paving the way for broader clinical applications.
Add comment